The objective of the technology transfer fund KHAN-I is to promote the specific implementation of research in therapeutic applications. Following a positive evaluation of the project proposal of Veronika Sexl and Karoline Kollmann of the Institute of Pharmacology and Toxicology at the University of Veterinary Medicine Vienna, both KHAN-I and w4i resolved to finance the project. For many years, the focus of the research project has been on cyclin-dependent kinase 6 (CDK6) and its role in cancer diseases. The goal of the project is to develop new medication to treat tumour diseases.
w4i and KHAN-I provide support to scientists by providing expertise in the fields of drug development and financing. The fund invests in the professional further development of academic (basic research) projects focusing on the development of new active pharmaceutical ingredients.
Read on and learn more about research funding in Austria!